These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 33555032)

  • 1. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pivotal Role of Translation in Anti-Infective Development.
    Friberg LE
    Clin Pharmacol Ther; 2021 Apr; 109(4):856-866. PubMed ID: 33523464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Call for Objective Dose Selection to Increase Success in Pediatric Clinical Trials: A Perspective From NICHD and NIMH Program Staff.
    Giacoia G; Grabb MC; Pawlyk AC; Ren Z; Samedy-Bates L; Taylor-Zapata P
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S9-S12. PubMed ID: 34185908
    [No Abstract]   [Full Text] [Related]  

  • 5. Model-Informed Drug Development in Pediatric Dose Selection.
    Bi Y; Liu J; Li F; Yu J; Bhattaram A; Bewernitz M; Li RJ; Ahn J; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S60-S69. PubMed ID: 34185906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial Dose Selection under the Animal Rule.
    Wu K; Choi SY; Bergman K; Seo S
    Clin Pharmacol Ther; 2021 Apr; 109(4):971-976. PubMed ID: 33565088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-Informed Drug Development Approaches to Assist New Drug Development in the COVID-19 Pandemic.
    Xiong Y; Fan J; Kitabi E; Zhang X; Bi Y; Grimstein M; Yang Y; Earp JC; Zheng N; Liu J; Wang Y; Zhu H
    Clin Pharmacol Ther; 2022 Mar; 111(3):572-578. PubMed ID: 34807992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends.
    Liu Q; Ahadpour M; Rocca M; Huang SM
    AAPS J; 2021 Apr; 23(3):54. PubMed ID: 33846878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Rao GG; Landersdorfer CB
    Int J Antimicrob Agents; 2021 Aug; 58(2):106368. PubMed ID: 34058336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.
    Roberts JK; Stockmann C; Constance JE; Stiers J; Spigarelli MG; Ward RM; Sherwin CM
    Clin Pharmacokinet; 2014 Jul; 53(7):581-610. PubMed ID: 24871768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resisting antimicrobial resistance.
    Nathan C
    Nat Rev Microbiol; 2020 May; 18(5):259-260. PubMed ID: 32300248
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China.
    Zhao M; Chen Y; Yang D; Lyu C; Bian X; Li X; Qiu W; Huang Z; Hu Z; Zhang J
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1466-1478. PubMed ID: 34651458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.
    Barker CI; Germovsek E; Hoare RL; Lestner JM; Lewis J; Standing JF
    Adv Drug Deliv Rev; 2014 Jun; 73(100):127-39. PubMed ID: 24440429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB.
    Vaddady PK; Lee RE; Meibohm B
    Future Med Chem; 2010 Aug; 2(8):1355-69. PubMed ID: 21359155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.